| Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa … E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ... PloS one 8 (7), e67946, 2013 | 153 | 2013 |
| Long‐term efavirenz autoinduction and its effect on plasma exposure in HIV patients E Ngaimisi, S Mugusi, OM Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ... Clinical Pharmacology & Therapeutics 88 (5), 676-684, 2010 | 133 | 2010 |
| Effect of Rifampicin and CYP2B6 Genotype on Long‐Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis E Ngaimisi, S Mugusi, O Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ... Clinical Pharmacology & Therapeutics 90 (3), 406-413, 2011 | 91 | 2011 |
| Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania S Mugusi, E Ngaimisi, M Janabi, O Minzi, M Bakari, KD Riedel, ... PloS one 7 (7), e40180, 2012 | 82 | 2012 |
| Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience F Mugusi, S Mugusi, M Bakari, B Hejdemann, R Josiah, M Janabi, ... Tropical medicine & international health 14 (10), 1226-1232, 2009 | 59 | 2009 |
| β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans RJ Hardwick, W Amogne, S Mugusi, G Yimer, E Ngaimisi, A Habtewold, ... The Journal of infectious diseases 206 (7), 1012-1019, 2012 | 53 | 2012 |
| Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method E Aklillu, S Mugusi, E Ngaimisi, MM Hoffmann, S König, V Ziesenitz, ... European journal of clinical pharmacology 67, 1139-1145, 2011 | 43 | 2011 |
| CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans E Aklillu, L Odenthal-Hesse, J Bowdrey, A Habtewold, E Ngaimisi, ... BMC infectious diseases 13, 1-10, 2013 | 38 | 2013 |
| SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine E Aklillu, A Habtewold, E Ngaimisi, G Yimer, S Mugusi, W Amogne, ... OMICS: A Journal of Integrative Biology 20 (9), 538-545, 2016 | 27 | 2016 |
| Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa LR Machado, J Bowdrey, E Ngaimisi, A Habtewold, O Minzi, E Makonnen, ... PloS one 8 (11), e78165, 2013 | 27 | 2013 |
| Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment E Ngaimisi, O Minzi, S Mugusi, P Sasi, KD Riedel, A Suda, N Ueda, ... Journal of Antimicrobial Chemotherapy 69 (12), 3311-3319, 2014 | 25 | 2014 |
| Effect of improved access to antiretroviral therapy on clinical characteristics of patients enrolled in the HIV care and treatment clinic, at Muhimbili National Hospital (MNH … SF Mugusi, JC Mwita, JM Francis, S Aboud, M Bakari, EA Aris, AB Swai, ... BMC Public Health 10, 1-7, 2010 | 25 | 2010 |
| Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania SF Mugusi, E Ngaimisi, MY Janabi, FM Mugusi, OMS Minzi, PG Sasi, ... Antiviral therapy 17 (2), 265-274, 2012 | 24 | 2012 |
| Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance … D Kamori, G Barabona, J Rugemalila, W Maokola, SS Masoud, ... Journal of Antimicrobial Chemotherapy 78 (3), 779-787, 2023 | 20 | 2023 |
| Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel prospective cohort … S Mugusi, A Habtewold, E Ngaimisi, W Amogne, G Yimer, O Minzi, ... Frontiers in Pharmacology 11, 26, 2020 | 17 | 2020 |
| Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second … J Svärd, S Mugusi, D Mloka, U Neogi, G Meini, F Mugusi, F Incardona, ... PloS one 12 (6), e0178942, 2017 | 17 | 2017 |
| Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin S Mugusi, E Ngaimisi, M Janabi, F Mugusi, O Minzi, E Aris, M Bakari, ... European Journal of Clinical Pharmacology 74, 1405-1415, 2018 | 15 | 2018 |
| The prevalence and pattern of antibiotic prescription among insured patients in Dar es Salaam Tanzania MA Khalfan, PG Sasi, SF Mugusi Pan African Medical Journal 40 (1), 2021 | 12 | 2021 |
| Adherence to combination antiretroviral therapy among orphaned children in Dar es Salaam, Tanzania SF Mugusi, N Mopei, O Minzi Southern African Journal of HIV Medicine 20 (1), 1-8, 2019 | 12 | 2019 |
| Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype EN Kitabi, OMS Minzi, S Mugusi, P Sasi, M Janabi, F Mugusi, L Bertilsson, ... Scientific Reports 8 (1), 16316, 2018 | 10 | 2018 |
Eliford Ngaimisi KitabiDivision of Pharmacometrics, FDA在 fda.hhs.gov 的电子邮件经过验证
